🚀 VC round data is live in beta, check it out!
Kelun Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kelun and similar public comparables like Nuvalent, Kyowa Kirin, Cytokinetics, Aurobindo Pharma and more.
Kelun Overview
About Kelun
Sichuan Kelun Pharmaceutical Co Ltd is a China-based pharmaceutical company focused on the manufacturing of infusion products, antibiotics, and various medical devices. The company operates its businesses through three segments. The Twinings segment focuses on producing pharmaceutical intermediates. The Botai segment is dedicated to the research, development, manufacturing, and commercialization of medicines. The Other Business segment covers activities such as the development and production of large-volume injections, along with the research, manufacturing, and sales of additional pharmaceutical products and related businesses.
Founded
2002
HQ
Employees
21.9K
Website
Sectors
Financials (LTM)
EV
$8B
Kelun Financials
Kelun reported last 12-month revenue of $3B and EBITDA of $513M.
In the same LTM period, Kelun generated $1B in gross profit, $513M in EBITDA, and $264M in net income.
Revenue (LTM)
Kelun P&L
In the most recent fiscal year, Kelun reported revenue of $3B and EBITDA of $572M.
Kelun expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $513M | XXX | $572M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $264M | XXX | $249M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 9% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kelun Stock Performance
Kelun has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Kelun's stock price is $5.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | 2.0% | XXX | XXX | XXX | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKelun Valuation Multiples
Kelun trades at 2.7x EV/Revenue multiple, and 14.7x EV/EBITDA.
EV / Revenue (LTM)
Kelun Financial Valuation Multiples
As of April 14, 2026, Kelun has market cap of $8B and EV of $8B.
Equity research analysts estimate Kelun's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kelun has a P/E ratio of 30.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 13.2x | XXX | XXX | XXX |
| EV/EBIT | 21.0x | XXX | 20.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | 5.8x | XXX | XXX | XXX |
| P/E | 30.8x | XXX | 32.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 50.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kelun Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kelun Margins & Growth Rates
Kelun's revenue in the last 12 month grew by 10%.
Kelun's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Kelun's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kelun's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kelun Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kelun Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kelun | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvalent | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyowa Kirin | XXX | XXX | XXX | XXX | XXX | XXX |
| Cytokinetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurobindo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Samchundang Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kelun M&A Activity
Kelun acquired XXX companies to date.
Last acquisition by Kelun was on XXXXXXXX, XXXXX. Kelun acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kelun
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKelun Investment Activity
Kelun invested in XXX companies to date.
Kelun made its latest investment on XXXXXXXX, XXXXX. Kelun invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kelun
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kelun
| When was Kelun founded? | Kelun was founded in 2002. |
| Where is Kelun headquartered? | Kelun is headquartered in China. |
| How many employees does Kelun have? | As of today, Kelun has over 21K employees. |
| Is Kelun publicly listed? | Yes, Kelun is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Kelun? | Kelun trades under 002422 ticker. |
| When did Kelun go public? | Kelun went public in 2010. |
| Who are competitors of Kelun? | Kelun main competitors are Nuvalent, Kyowa Kirin, Cytokinetics, Aurobindo Pharma. |
| What is the current market cap of Kelun? | Kelun's current market cap is $8B. |
| What is the current revenue of Kelun? | Kelun's last 12 months revenue is $3B. |
| What is the current revenue growth of Kelun? | Kelun revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Kelun? | Current revenue multiple of Kelun is 2.7x. |
| Is Kelun profitable? | Yes, Kelun is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kelun? | Kelun's last 12 months EBITDA is $513M. |
| What is Kelun's EBITDA margin? | Kelun's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Kelun? | Current EBITDA multiple of Kelun is 14.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.